Cyclopentobarbital(5)

Catalogue: Size:  
PAS9644 100µg
Specifications
Description Barbiturates are a class of around 12 compounds derivatised from barbituric acid. They are central nervous system (CNS) depressants and can be used as sedatives, hypnotics, anaesthetics and anti-epileptic drugs. Barbiturates can be divided into three main groups according to their duration of action. The ultra-short-acting barbiturates are used clinically as anaesthetics whilst the long-acting barbiturates have anti-convulsant properties. The short-acting compounds are typically used as hypnotics(1, 2). The short-acting barbiturates are extensively metabolised by the liver to more pharmacologically inactive hydroxylated compounds. Only a small proportion of parent compound (<0.2%) appears in the urine collected after 24 hours. However, with large doses, there is usually sufficient of the parent compound present to give an adequate response and some of the hydroxylated metabolites will also cross-react in immunoassays(1).
Sample Volume 100µg
Buffer 20mM Phosphate, 150mM Sodium Chloride, pH 7.2
Format Ig fraction
Host Sheep
Ig Con 11.65mg/ml (U.V.abs @ 280nm)
Immunogen Cyclopentobarbital (5)-BTG
Lot RS661-B10
Preservative 0.09% Sodium Azide
Storage ≤ -20C, avoid repeated freeze/thaw cycles
Work Con 2.5μg/ml (EIA)
References 1. Galloway J.H. and Marsh I.D. Detection of drug misuse and addictive challenge. J. Clin. Pathol.1999. 52 (10): 713-718. 2. Manchikanti, L. Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Pain Physician. 2006. 9(4): 287-321.